CytRx Corp. (CYTR)

1.57
0.01 0.32
NASDAQ : Health Technology
Prev Close 1.57
Open 1.60
Day Low/High 1.57 / 1.60
52 Wk Low/High 1.50 / 5.99
Volume 4.47K
Avg Volume 329.80K
Exchange NASDAQ
Shares Outstanding 27.64M
Market Cap 42.56M
EPS -3.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

CytRx Corporation Regains Nasdaq Listing Compliance

CytRx Corporation Regains Nasdaq Listing Compliance

Hires Investigation Firm to Initiate Short Selling Audit

CytRx Corporation Highlights Recent Progress At Freiburg, Germany, Laboratory And Provides Update For Oncology Pipeline

CytRx Corporation Highlights Recent Progress At Freiburg, Germany, Laboratory And Provides Update For Oncology Pipeline

Company's Goal is to Create a New Class of Rationally Designed, Breakthrough Anti-Cancer Drugs

CytRx Corporation Announces Reverse Stock Split

CytRx Corporation Announces Reverse Stock Split

Shares of Common Stock Will Begin Trading on a Post-Split Basis on November 1, 2017

CytRx Corporation Announces Results From Special Meeting Of Stockholders

CytRx Corporation Announces Results From Special Meeting Of Stockholders

Stockholders Approve Reverse Stock Split Proposal by More Than Double FOR to One AGAINST

CytRx Corporation Announces Outcome Of Nasdaq Hearing

CytRx Corporation Announces Outcome Of Nasdaq Hearing

Listing Extension Granted Pending Results of Stockholder Vote

CytRx Corporation Announces Amendment To Definitive Proxy Statement For Upcoming Special Meeting

CytRx Corporation Announces Amendment To Definitive Proxy Statement For Upcoming Special Meeting

- Authorized Common and Preferred Shares to be Reversed on Same One-for-Six Ratio as Issued and Outstanding Shares

CytRx Corporation Announces Receipt Of NASDAQ Listing Determination

CytRx Corporation Announces Receipt Of NASDAQ Listing Determination

- Company to Request Hearing -

CytRx Corporation Files Preliminary Proxy Statement For Upcoming Special Meeting

CytRx Corporation Files Preliminary Proxy Statement For Upcoming Special Meeting

Company Seeks to Avoid Delisting from NASDAQ

CytRx Corporation Announces Global Strategic License With NantCell Inc. For Aldoxorubicin, An Albumin Mediated Chemotherapeutic

CytRx Corporation Announces Global Strategic License With NantCell Inc. For Aldoxorubicin, An Albumin Mediated Chemotherapeutic

NantCell to Expand the Development of Aldoxorubicin into Multiple Tumor Types in Combination with Immuno-Oncology and Cell-Based Therapies

Interesting CYTR Call Options For March 2018

Investors in CytRx Corp saw new options begin trading today, for the March 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

CytRx Announces Reshaping Of Clinical And Regulatory Executive Team

- Dr. Shanta Chawla promoted to Senior Vice President of Drug Development -

CytRx Announces Update On The Regulatory Pathway For Aldoxorubicin In Soft Tissue Sarcomas

- Current Clinical and Preclinical Data Can Support Approval

Goodbye CytRx, Your Game Is Over

Goodbye CytRx, Your Game Is Over

Hope springs eternal, until it's dashed on the rocks and buried at sea.